⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RIGL News
Rigel Pharmaceuticals Inc. (New)
Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight
globenewswire.com
TLRY
TAK
TNDM
NVS
BMY
PFE
INCY
JNJ
AZN
MRK
ABBV
CRSP
SCLX
RIGL
JAZZ
GILD
REGN
AMGN
BIIB
PTGX
EXAS
SNOW
SRPT
VRTX
BNTX
ALKS
RGEN
IMUX
ADPT
ATRC
CRNX
CYTK
DTIL
EXEL
FGEN
GALT
GNTX
GRFS
GSK
HRMY
IDXX
ILMN
INSM
IONS
IRWD
KODK
LAKE
LULU
LYFT
MAR
MDLZ
MELI
MIRM
MNKD
MRNA
MTCH
NBIX
NCLH
NEM
NTRA
NVCR
ODFL
OMER
ORGO
OTEX
PACB
PBYI
PCAR
PEGA
PERI
PETS
PLRX
PMVP
PPC
PRGS
PRTA
PSNL
PTN
PZZA
QGEN
QTRX
RARE
RCEL
RDHL
RLAY
RLGT
RMD
ROST
RRX
RYAAY
RYTM
SAN
SBAC
SBRA
SEIC
SIGA
SIRI
SITE
SLAB
SLGN
SMCI
SMMT
SNPS
SNY
SOFI
SONO
SPCE
SSYS
STNG
STRA
STRL
STX
SWKS
SYK
SYNA
TCOM
TDOC
TECK
TEVA
TFX
TGTX
TIGR
TRMB
TRVG
TTWO
TUSK
TXRH
ULTA
UMC
UNFI
UNH
URBN
UTHR
VEEV
VELO
VERU
VIVO
VKTX
VLRS
VNDA
VRSK
VSAT
VTGN
WDC
WEC
WERN
WGO
WIX
WMB
WST
WTW
WYNN
XOM
XPER
XPO
XRAY
YETI
YRD
YUM
ZBRA
ZLAB
ZYME
Rigel to Participate in Upcoming September Investor Conferences
prnewswire.com
RIGL
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Colombia
globenewswire.com
RIGL
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
prnewswire.com
RIGL
Synthekine Appoints Veteran Biotech Leader Susan M. Molineaux, Ph.D. as Chief Executive Officer
businesswire.com
RIGL
GERN
Form 8-K
sec.gov
RIGL
Rigel Reports Second Quarter 2026 Financial Results
prnewswire.com
RIGL
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
ARVN
RIGL
STARTRADER expands AI offering with 31 New US Share & ETF CFDs in Semiconductors, Optical Networking & Nuclear
prnewswire.com
ON
WOLF
ASTL
RIGL
SMTC
VSH
AXTI
VRT
CIEN
APO
FABC
NOK
Onco360® Has Been Selected as a National Pharmacy Partner for VEPPANU™ (vepdegestrant)
globenewswire.com
RIGL